Meanwhile, transwell assay results indicated that MK2206 treatment significantly inhibited the migration and invasion of UPP1-overexpressing BLCA cells (Fig. 4D-E and Supplementary Fig. S8D-E). The gene discussed is UPP1; the disease is bladder transitional cell carcinoma.